Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 10/20 | 0.44 |
| ▸ | MPC2 | O95563 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9532951 | 0.93 | MEN1 (0.58) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| SCHEMBL9631327 | 0.92 | MEN1 (0.54) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| SCHEMBL5086147 | 0.91 | MEN1 (0.52) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| SCHEMBL10641870 | 0.91 | MEN1 (0.52) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| SCHEMBL9632297 | 0.91 | MEN1 (0.52) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL15888838 | 0.90 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL5672808 | 0.90 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL1536757 | 0.90 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL21630 | 0.90 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL5672813 | 0.90 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | CHEN JAMES M | 2009-05-21 | — | — | US | disclosed |
| US-20040224995-A1 | Neuroprotective effects of PPARy agonists against cellular oxidative insults | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224995-A1 | Neuroprotective effects of PPARy agonists against cellular oxidative insults | PPARG, PPARA, PPARD | MEN1 4871/4885MAPT 1542/4885KMT2A 4537/4885 |
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | PHOSPHO1, G6PC1, PC | MEN1 836/4885MAPT 1774/4885KMT2A 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.